"HIV Protease Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly.
| Descriptor ID |
D017320
|
| MeSH Number(s) |
D27.505.519.389.745.420 D27.505.954.122.388.077.088.420
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "HIV Protease Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "HIV Protease Inhibitors".
This graph shows the total number of publications written about "HIV Protease Inhibitors" by people in this website by year, and whether "HIV Protease Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 1 | 0 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2002 | 3 | 0 | 3 |
| 2003 | 1 | 1 | 2 |
| 2007 | 2 | 1 | 3 |
| 2009 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "HIV Protease Inhibitors" by people in Profiles.
-
Drug Interactions With a Short Course of Nirmatrelvir and Ritonavir: Prescribers and Patients Beware. J Clin Pharmacol. 2022 08; 62(8):925-927.
-
ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer. Radiother Oncol. 2016 05; 119(2):306-11.
-
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing. Clin Pharmacol Ther. 2016 Apr; 99(4):363-9.
-
Mortality and long-term virologic outcomes in children and infants treated with lopinavir/ritonavir. Pediatr Infect Dis J. 2013 Dec; 32(12):e466-72.
-
Quantized water access to the HIV-1 protease active site as a proposed mechanism for cooperative mutations in drug affinity. Biochemistry. 2012 Aug 21; 51(33):6487-9.
-
Dynamics of "flap" structures in three HIV-1 protease/inhibitor complexes probed by total chemical synthesis and pulse-EPR spectroscopy. J Am Chem Soc. 2009 Jan 28; 131(3):884-5.
-
Crystal structure of chemically synthesized HIV-1 protease and a ketomethylene isostere inhibitor based on the p2/NC cleavage site. Bioorg Med Chem Lett. 2008 Aug 15; 18(16):4554-7.
-
Scutellaria baicalensis and a constituent flavonoid, baicalein, attenuate ritonavir-induced gastrointestinal side-effects. J Pharm Pharmacol. 2007 Nov; 59(11):1567-72.
-
Insights from atomic-resolution X-ray structures of chemically synthesized HIV-1 protease in complex with inhibitors. J Mol Biol. 2007 Oct 26; 373(3):573-86.
-
Darunavir in the treatment of HIV-1 infection: a viewpoint by Renslow Sherer. Drugs. 2007; 67(18):2802-3.